Mineralocorticoid receptor antagonists for heart failure: a real-life observational study

Investigating, in a population-based analysis, the long-term effects of Mineralocorticoid receptor antagonists treatment in reduced ejection fraction heart failure patients (ESC Heart Fail 2018 Feb 4)

12 Febbraio Feb 2018 8 days ago
  • Bonomi A, Veglia F, Salvioni E, Contini M, Apostolo A, Palermo P, Mapelli M, Agostoni P

Mineralocorticoid receptor antagonists (MRAs) have been demonstrated to improve outcomes in reduced ejection fraction heart failure (HFrEF) patients. However, MRAs added to conventional treatment may lead to worsening of renal function and hyperkalaemia. The Authors investigated, in a population-based analysis, the long-term effects of MRA treatment in HFrEF patients.

Reference

  • Bruno N, Sinagra G, Paolillo S, Bonomi A, Corrà U, Piepoli M, Veglia F, Salvioni E, Lagioia R, Metra M, Limongelli G, Cattadori G, Scardovi AB, Carubelli V, Scrutino D, Badagliacca R, Guazzi M, Raimondo R, Gentile P, Magrì D, Correale M, Parati G, Re F, Cicoira M, Frigerio M, Bussotti M, Vignati C, Oliva F, Mezzani A, Vergaro G, Di Lenarda A, Passino C, Sciomer S, Pacileo G, Ricci R, Contini M, Apostolo A, Palermo P, Mapelli M, Carriere C, Clemenza F, Binno S, Belardinelli R, Lombardi C, Perrone Filardi P, Emdin M, Agostoni P. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. ESC Heart Fail 2018 Feb 4. doi: 10.1002/ehf2.12244. [Epub ahead of print] Go to PubMed